Shufro Rose & Co’s AbbVie ABBV Stock Holding History

Shufro Rose & Co’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$743K	Hold	3,415	–	–	0.05%	141
2025 Q4	$780K	Buy	3,415 +200	+6%	+$45.6K	0.05%	138
2025 Q3	$674K	Hold	3,215	–	–	0.06%	146
2025 Q2	$674K	Hold	3,215	–	–	0.05%	146
2025 Q1	$674K	Hold	3,215	–	–	0.05%	147
2024 Q4	$571K	Sell	3,215 -230	-7%	-$42.3K	0.04%	160
2024 Q3	$591K	Hold	3,445	–	–	0.05%	159
2024 Q2	$591K	Buy	3,445 +50	+1%	+$8.28K	0.05%	159
2024 Q1	$618K	Buy	3,395 +300	+10%	+$51.7K	0.05%	146
2023 Q4	$461K	Hold	3,095	–	–	0.04%	165
2023 Q3	$461K	Sell	3,095 -161	-5%	-$23.6K	0.04%	165
2023 Q2	$439K	Hold	3,256	–	–	0.04%	179
2023 Q1	$519K	Sell	3,256 -200	-6%	-$30.6K	0.05%	168
2022 Q4	$559K	Sell	3,456 -9	-0.3%	-$1.38K	0.05%	162
2022 Q3	$465K	Buy	3,465 +1,509	+77%	+$217K	0.05%	166
2022 Q2	$300K	Buy	1,956 +100	+5%	+$15.3K	0.03%	223
2022 Q1	$301K	Sell	1,856 -94	-5%	-$13.7K	0.02%	230
2021 Q4	$264K	Hold	1,950	–	–	0.02%	249
2021 Q3	$210K	Sell	1,950 -66	-3%	-$7.54K	0.02%	263
2021 Q2	$227K	Sell	2,016 -75,240	-97%	-$8.47M	0.02%	253
2021 Q1	$8.36M	Sell	77,256 -5,019	-6%	-$537K	0.66%	38
2020 Q4	$8.82M	Sell	82,275 -3,479	-4%	-$334K	0.74%	38
2020 Q3	$7.51M	Sell	85,754 -6,066	-7%	-$571K	0.72%	37
2020 Q2	$9.02M	Buy	+91,820	New	+$8.08M	0.89%	33
2020 Q1	–	Sell	-2,925	Closed	-$259K	–	295
2019 Q4	$259K	Sell	2,925 -1,000	-25%	-$83K	0.02%	247
2019 Q3	$297K	Sell	3,925 -51	-1%	-$3.5K	0.03%	225
2019 Q2	$289K	Buy	3,976 +1,051	+36%	+$82.6K	0.03%	225
2019 Q1	$236K	Hold	2,925	–	–	0.02%	244
2018 Q4	$270K	Buy	2,925 +100	+4%	+$8.79K	0.03%	219
2018 Q3	$267K	Buy	2,825 +350	+14%	+$33.2K	0.02%	239
2018 Q2	$229K	Buy	2,475 +320	+15%	+$31.3K	0.02%	249
2018 Q1	$204K	Sell	2,155 -100	-4%	-$11K	0.02%	264
2017 Q4	$218K	Sell	2,255 -475	-17%	-$44.8K	0.02%	253
2017 Q3	$243K	Buy	+2,730	New	+$208K	0.02%	246
2015 Q1	–	Sell	-88,700	Closed	-$5.8M	–	264
2014 Q4	$5.8M	Sell	88,700 -400	-0.4%	-$25.2K	0.59%	55
2014 Q3	$5.15M	Hold	89,100	–	–	0.53%	61
2014 Q2	$5.03M	Sell	89,100 -500	-0.6%	-$26.2K	0.52%	61
2014 Q1	$4.61M	Sell	89,600 -4,300	-5%	-$217K	0.48%	60
2013 Q4	$4.96M	Buy	93,900 +4,750	+5%	+$233K	0.52%	54
2013 Q3	$3.99M	Sell	89,150 -3,150	-3%	-$140K	0.45%	60
2013 Q2	$3.81M	Buy	+92,300	New	+$4.04M	0.45%	61

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Shufro Rose & Co's ABBV Position: Q1 2026 in Review

Shufro Rose & Co held its AbbVie (ABBV) position steady in Q1 2026 at 3,415 shares worth $743K. The position accounts for 0.05% of the portfolio, ranked #141.

Shufro Rose & Co first reported a position in ABBV in Q2 2013 and has held it in 41 quarters since. The position peaked at $9.02M in Q2 2020. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Shufro Rose & Co held 3,415 shares of AbbVie worth $743K as of Q1 2026.
Shufro Rose & Co left its AbbVie share count unchanged in Q1 2026.
AbbVie made up 0.05% of Shufro Rose & Co's portfolio in Q1 2026, its #141 holding.
Shufro Rose & Co first reported a position in AbbVie in Q2 2013 and has held it in 41 quarters since.
Shufro Rose & Co's AbbVie position peaked at $9.02M in Q2 2020.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Shufro Rose & Co's 13F filing for Q1 2026, filed 15 May 2026.